Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

August 14, 2018

Conditions
Ovarian CancerEndometrial CancerUterine Cervical Cancer
Interventions
DRUG

Filgrastim

All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.

DRUG

Paclitaxel

All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.

DRUG

Carboplatin

All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.

Trial Locations (17)

2570

St. Maarten Duffel, Duffel

2650

UZ Antwerpen, Edegem

2820

Imeldaziekenhuis, Bonheiden

2930

AZ Klina, Brasschaat

3000

UZ Leuven, Leuven

4000

Centre Hospitalier Régional de la Citadelle, Liège

CHU Sart Tilman Liège, Liège

5000

Cliniques et maternité St. Elizabeth, Namur

5530

Cliniques universitaires UCL de Mont-Godinne, Yvoir

6000

Grand Hôpital de Charleroi, Charleroi

6700

Cliniques du Sud-Luxembourg, Arlon

6800

Centre Hospitalier de l'Ardenne, Libramont

7100

CHU Tivoli, La Louvière

8400

AZ Damiaan, Ostend

8500

AZ Groeninge, Kortrijk

8900

Jan Yperman Ziekenhuis, Ieper

9100

AZ Nikolaas, Sint-Niklaas

All Listed Sponsors
lead

Belgian Gynaecological Oncology Group

OTHER

NCT01523678 - Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | Biotech Hunter | Biotech Hunter